LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

25.39 6.82

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.21

Max

25.61

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.8M

-57M

Pardavimai

35K

730K

Pelnas, tenkantis vienai akcijai

-1.01

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-1.1M

-63M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+105.68% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

58M

1.5B

Ankstesnė atidarymo kaina

18.57

Ankstesnė uždarymo kaina

25.39

Naujienos nuotaikos

By Acuity

50%

50%

160 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-14 17:45; UTC

Uždarbis
Pagrindinės rinkos jėgos

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

2025-11-14 17:31; UTC

Uždarbis
Pagrindinės rinkos jėgos

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

2025-11-15 18:03; UTC

Uždarbis

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

2025-11-15 15:43; UTC

Uždarbis

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

2025-11-15 12:00; UTC

Uždarbis

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

2025-11-15 09:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-11-15 09:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-11-15 00:08; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

2025-11-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

2025-11-14 23:02; UTC

Rinkos pokalbiai

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

2025-11-14 22:35; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

2025-11-14 22:32; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

2025-11-14 22:29; UTC

Uždarbis

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

2025-11-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

2025-11-14 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-11-14 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

2025-11-14 20:27; UTC

Rinkos pokalbiai

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

2025-11-14 20:23; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

2025-11-14 20:17; UTC

Įsigijimai, susijungimai, perėmimai

Several State Attorneys General Oppose Railroad Merger -- WSJ

2025-11-14 19:29; UTC

Rinkos pokalbiai
Uždarbis

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

2025-11-14 18:44; UTC

Rinkos pokalbiai
Uždarbis

Disney's Growth Now Hinges More on ESPN -- Market Talk

2025-11-14 18:27; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-11-14 18:27; UTC

Rinkos pokalbiai

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

2025-11-14 18:20; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

2025-11-14 17:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-11-14 17:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-11-14 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-11-14 16:51; UTC

Rinkos pokalbiai

Starbucks Gets Holiday Sales Lift -- Market Talk

2025-11-14 16:48; UTC

Rinkos pokalbiai

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

2025-11-14 16:38; UTC

Rinkos pokalbiai

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

105.68% į viršų

12 mėnesių prognozė

Vidutinis 52.55 USD  105.68%

Aukščiausias 90 USD

Žemiausias 21 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

12

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

160 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat